ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 211

Efficacy and Safety of Disease Modifying Drugs, Biologic Therapies and Immunoglobulin in Patients with Polymyositis and Dermatomyositis: A Systematic Literature Review

JA Martinez-Lopez Sr.1, J. Graña Sr.2, Santiago Muñoz-Fernandez3, I. Rua-Figueroa4, José M. Pego-Reigosa5, Estíbaliz Loza Sr.6 and SER group for the study of systemic autoimmune diseases7, 1Fundacion Jimenez Diaz, Madrid, Spain, 2Hospital Juan Canalejo, Spain, 3Unit Rheumatology, Hospital Infanta Sofía, Madrid, Spain, 4Rheumatology, Hospital de GC Dr Negrin, Las Palmas GC, Spain, 5Rheumatology, Hospital do Meixoeiro, Vigo, Spain, 6Research Unit. Sociedad Española de Reumatología, Madrid, Spain, 7Madrid

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Disease-modifying antirheumatic drugs, infliximab, polymyositis/dermatomyositis (PM/DM) and rituximab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Clinical and Therapuetic Aspects of Idiopathic Inflammatory Myopathies

Session Type: Abstract Submissions (ACR)

Background/Purpose: The aim of this study was to systematically review the efficacy and safety of available drugs in patients with polymyositis (PM) or dermatomyositis (DM)

Methods: We systematically searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials up to October 2011 using a comprehensive search strategy for disease modifying drugs (DMARD), biologic therapies, intravenous immunoglobulins (IVIG), primary PMS and DPM, efficacy and safety (mesh terms and text words). Selection criteria were predefined by protocol. We selected meta-analysis, systematic literature reviews, clinical trials (CT), that included >18 year-old patients primary PMS and DM on the selected drugs, English, Spanish and French languages. Studies including patients with secondary PMS or DM, and basic science studies were excluded. Title and abstract selection and subsequent detailed review of selected articles were independently performed by two reviewers. A hand search of the selected articles was performed. The included studies quality was graded using the Oxford Levels of Evidence Scale, and results expressed as level of evidence (LE), recommendation grade (RG).

Results: The search strategy identified 2,442 potentially relevant articles, of which 114 were selected for full paper review. Twenty articles were eventually included in the analysis. The selection included 7 randomized CT, 13 open trials, which analyzed 334 patients. Main characteristics and results are shown in the table.

Conclusion: Rituximab is effective to achieve remission in patients with PM/DM refractory to standard therapy (high dose prednisone and DMARD), (LE 2b; GR B-C). There is no current evidence on the efficacy of infliximab in patients with PM/DM (LE 2b; GR B-C). The addition of etanercept to steroids does not increase response rate or decreased adverse events (LE 1c, GR B), but could be useful as steroids sparring in DM patients (LE 1c, GR B). The addition of azathioprine to steroids does not increase response rate or decreased adverse events in DM patients (LE 2b; GR B-C). IVIG are effective to achieve remission in patients with PM/DM refractory to DMARD (LE 2b, GR B-C).

Table 1. Main results of the systematic literature review.

Study

Efficacy

Amato (2011),

RCT (n=16 DM), 52 w, Oxford 1c

ETA vs PCB

– Improvement on IMACS: ETA/PCB 55%/60%

– Prednisone stop: ETN/PCB 73%/20%, p<0,001

-Median time to treatment failure: ETA/PCB 358 d/148 d,  p<0,001

Bunch (1978),

RCT (n=14 PM), 12 w,  Oxford 2b

AZA vs PCB

-Muscle biopsy: AZA/PCB improvement, p>0,050

-MMT: improvement, AZA/PCB improvement, p>0,050

Bunch (1980)

RCT (n=16 PM), 12 w, Oxford 2b

AZA vs PCB

-CPK levels: AZA/PCB improvement, p>0,050

-Muscular strength AZA/PCB improvement, p=0,580

-Muscle biopsy: AZA/PCB improvement, p>0,050

Dalakas (1993)

RCT (n=15 DM), 24 w, Oxford 1c

IVIG (1 infusion) vs PCB

-Neuromuscular symptoms and scores of muscular strength: IG more improvement than PCB, p<0,018 p<0,035

-Muscle biopsy of IG patients: clear improvement

Fries (1973)

RCT (n=8 PM), 16 w, Oxford 2b

CYC vs PDN

-Disease activity: CYC 5/5 worsened; PDN 3/3 improvement

Miyasaka (2011)

RCT (n=26 PM/DM), 26 w, Oxford 1b

IVIG vs PCB

-MMT: IG/PCB improvement 92%/57%, p>0,050

–Dysphagia: IVIG ceased 5/7 (71%), PCB no improvement 2/2 (100%), p=0.167

-ADL score: IG/PCB improvement  p>0,050

-CPK levels: IG/PCB improvement  p>0,050

Vencovsky (2000)

RCT (n=36 PM/DM), 24 w, Oxford 1c

MTX vs CyA

-Muscle endurance and functional test: MTX/CyA improvement 29%/47%, p>0,050 

-Clinical assessment: MTX/CyA improvement  65%/58%, p>0,050 

-Global patient assessment: MTX/CyA improvement  59%/68%, p>0,050   

-Muscle MRI: MTX/CyA improvement, p>0,050 

-CPK levels: MTX normal levels, CyA elevated

-ANA +: MTX/CyA 76%/ 68%, p>0,050 

Cherin (2002)

OT (n=35 PM), 3 yr, Oxford 2b

IVIG

-Muscle power: improvement 25/35 (71%)

-Muscle disability scale score: improvement 28/35 (80%)

-Esophageal disorders: ceased 8/11 (27%)

-Relapses: 7/25 (28%)

-Steroids reduction: 22/35 (63%)

-CPK levels: normal 19/33 (58%), improvement 14/33 (42%)

Cherin (1994)

OT (n=11), 16 w, Oxford 2b

IVIG

-British Medical Council Research grading system: improvement 3/11 (27%)

-CPK levels: reduction 8/11 (73%)

Chung (2007)

OT (n=8 DM), 24 w, Oxford 2b

RTX

-Partial remission: 3/8 (38%)

-Muscle enzyme levels and skin scores: not significantly changed from those at baseline

Dastmalchi (2008)

OT (n=13 PM/DM), 16 w, Oxford 2b

IFX

-IMACS: improvement 3/9 (33%), worsened 3/9 (33%)

-MMT: no improvements

-Muscle MRI: worsened 5 patients

-Muscle biopsy: no changes from baseline

García Hernán. (2010),

OT (n=14 PM/DM), 1 yr, Oxford 2b

RTX + CYC

–Comlete or partial remission 1 m/6 m/1yr: 65%/100%/64%

-British Medical Research Council grading system: improvement 100%

-5 relapses, median of time to relapse: 11 m

-Significant decreased: EGS, CPK, Mb, LDH

–Pulmonary function: improvement 75%

Hara (2003)

OT (n=11), 12 w,

Oxford 2b

IVIG

-MMT: improvement 7/8 (88%)

-ADL score: improvement 7/8 (88%)

-CPK levels: improvement 7/8 (88%)

Hengstman (2008)

OT (n=6 PM/DM), 26 w, Oxford 2b

IFX + MTX

-Patient and physician disease activity assessment, MMT, handheld dynamometry: improved

-CPK levels: improved 2/6 (33%)

Kameda (2005)

OT (n=10 DM + interstitial pneumonia), Oxford 2b

Prednisolone + CYC + CyA

– 5 survived for > 2 yr well

Levine (2005)

OT (n=7 DM), 52 w, Oxford 2b

RTX

-MMT: improvement 6/7 (86%)

-Rash, alopecia, and reduced forced vital capacity, improved markedly

-4 relapses

Mastaglia (1998)

OT (n=7 PM/DM), Oxford 2b

IVIG

-Complete or partial remission: 5/7 (71%)

–Fuerza muscular: improvement 5/7 (71%)

-CPK levels: normalization 5/7 (71%)

Mok (2007)

OT (n=4 PM), 28 w, Oxford 2b

RTX

–Promimal muscle power scores: improved 100%

-CPK levels: improvement 100%, 2 normalization

-HAQ: improvement 100%

-Disability scores, SF-36: trend to improvement

Saito (2008)

OT (n=15 PM/DM), 12 w, Oxford

IGIV

-MMT: improvement 14/15 (93%)

-ADL score: improvement 12/15 (80%)

-CPK levels: improvement 15/15 (100%)

Tokano (2002)

OT (n=11 DM/PM), 24 w, Oxford 2b

CyA

-Respiratory sympthoms improveement, ↑ PaO2>10 mmHg, ↑ %DLCO, improvement chest radiology/TACAR, ↓steroids doses >10%, ↓ LDH>25%:  7/11 (64%) maintained improvement

Abbreviations: PM=polymyositis; DM=dermtomyositis: w=week; m=month; yr=year; ETA=etanercept; PCB=placebo; AZA= azathioprine; CPK=creatine phosphokinase; CYC=cyclophosphamide; PDN=prednisone; CyA= cyclosporine A; MTX= methotrexate; IVIG=intravenous immunoglobulins; RTX=rituximab; IFX=infliximab; MMT=Manual muscle tests; ADL= activities of daily living; EGS= erythrocyte globular sedimentation; LDH= L-lactate dehydrogenase; IMACS=International Myositis Assessmenet Clinical Studies; HAQ=health assessment questionnaire.


Disclosure:

J. Martinez-Lopez Sr.,
None;

J. Graña Sr.,
None;

S. Muñoz-Fernandez,
None;

I. Rua-Figueroa,
None;

J. M. Pego-Reigosa,
None;

E. Loza Sr.,
None;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-disease-modifying-drugs-biologic-therapies-and-immunoglobulin-in-patients-with-polymyositis-and-dermatomyositis-a-systematic-literature-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology